Fig. 1, Lambotin et al.

p=0.023 n.s. n.s. A BDCA2 CD11c IL-3R CD80 CD86 pDCs mDCs B CD81 SR-BI CLDN1 DC-SIGN pDCs mDCs C Fig. 1, Lambotin et al.

107 107 106 106 105 105 104 104 103 103 102 102 101 101 100 100 NC NC rat IgG rat IgG PBS PBS Anti-SR-BI Anti-SR-BI Anti-CD81 Anti-CD81 mouse IgG mouse IgG Anti-DC-SIGN Anti-DC-SIGN Anti-CLDN1 Anti-CLDN1 B C NC + HCVcc overlay Anti-E2 Anti-core pDCs pDCs mDCs mDCs pDCs mDCs p = 0.012 100 100 120 100 80 80 80 60 60 % inhibition of HCVcc utpake % inhibition of HCVcc utpake 60 40 40 40 20 20 20 0 0 0 pDCs mDCs Anti-HCV Anti-HCV Anti-SR-BI Anti-SR-BI Anti-CD81 Anti-CD81 Anti-CLDN1 Anti-CLDN1 A pDCs mDCs Copies HCV RNA/ µg cellular RNA Copies HCV RNA/ µg cellular RNA D E number of E2 positive cells/ total number of cells (n=300) Fig. 2, Lambotin et al.

HCV E2 HCV E2 Rab5 Rab5 Overlay Overlay HCV E2 HCV E2 Lamp1 Lamp1 Overlay Overlay HCV E2 HCV E2 CD71 CD71 Overlay Overlay pDCs mDCs A B CD71 MHC I Overlay Lamp1 MHC I Overlay CD71 MHC II Overlay Lamp1 MHC II Overlay Fig. 3, Lambotin et al.

Fig. 1, Lambotin et al.

Fig. 1, Lambotin et al.

Presentation Transcript

Daniel et al Suppl . Fig . 1

Wolff et al, GRL 2012 – Fig. 1

Rozas et al. Fig. 1

Supplement Fig . 1. Kim et al.

Rezzonico et al. – Fig. S1A

Wang et al., Supplementary Fig. 1

Miao et al., Fig. S1

Gesell et al., Suppl. Fig. 1

Brückner et al., Fig. 1b

Lall et al. Suppl. Fig. 1

Fig. S1 . Okubo et al.

Supplementary Fig. 1, Deo et al

Online Fig . 1 Jian et al.

Fig. S4 Swarup et al

Imamura et al. Fig. S1A

Jungwirth et al. Suppl. Fig. 1

Teng et al. Fig. S1

Baumgarten et al. (2012) Fig. 1

Vickerman et al., Supplementary Fig. 1

Lall et al. Suppl. Fig. 1